Enanta Pharmaceuticals | ENTA - Assets


Enanta Pharmaceuticals reported $329.5M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
AbbVie USD 135.12B 1.35B Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
Anika Therapeutics USD 183.47M 4.09M Jun/2026
Arrowhead Research USD 2.11B 156.25M Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
BioCryst Pharmaceuticals USD 557.85M 92.8M Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Gilead Sciences USD 49.36B 6.92B Jun/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
Halozyme Therapeutics USD 2.58B 95.31M Jun/2026
Heron Therapeutics USD 252.26M 6.05M Jun/2026
Immunic USD 189.74M 165.69M Mar/2026
Incyte USD 7.87B 533.53M Jun/2026
Insmed USD 2.1B 26.7M Jun/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
J&J USD 201.06B 167M Jun/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Ligand Pharmaceuticals USD 2.19B 653.77M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Novavax USD 955.58M 87.59M Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sarepta Therapeutics USD 3.19B 9.58M Jun/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026